secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000078003-25-000136
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10
--------------------------------------------------------------------------------

- Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.
- FY 2025 revenue guidance reaffirmed at $61B-$64B; adjusted EPS guidance raised by $0.10 to $2.90-$3.10.
- Vyndaqel family revenue up 21% operationally; Comirnaty +95%; Paxlovid +71%; Padcev +38%; Eliquis +6%.
- Completed $1.25B upfront in-licensing of 3SBio's SSGJ-707; one-time ~$0.20 EPS impact in Q3.
- On track for $7.2B net cost savings by end of 2027; capital allocation includes $4.9B dividends in H1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/0000078003-25-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000078003-25-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer